| 0.478 0.088 (22.63%) | 02-07 15:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.48 | 1-year : | 0.49 |
| Resists | First : | 0.41 | Second : | 0.41 |
| Pivot price | 0.4 |
|||
| Supports | First : | 0.39 | Second : | 0.33 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.4 |
| MA(100) : | 0.41 |
MA(250) : | 0.36  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 13.8 |
D(3) : | 8.5 |
| RSI | RSI(14): 44.1 |
|||
| 52-week | High : | 0.46 | Low : | 0.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SIOX ] has closed above bottom band by 24.3%. Bollinger Bands are 42.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 55 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.41 - 0.41 | 0.41 - 0.41 |
| Low: | 0.4 - 0.4 | 0.4 - 0.4 |
| Close: | 0.4 - 0.4 | 0.4 - 0.4 |
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Fri, 02 Feb 2024
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share - GlobeNewswire
Wed, 15 Mar 2023
SIO GENE THERAPIES INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ... - Marketscreener.com
Tue, 14 Feb 2023
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results - GlobeNewswire
Wed, 02 Feb 2022
Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022 - GlobeNewswire
Fri, 05 Nov 2021
Sio Gene Therapeutics Inc. (NASDAQ: SIOX) Announce Executive Reorganisation and Receives Fast Track ... - BP Journal
Mon, 13 Sep 2021
Quite a few insiders invested in Sio Gene Therapies Inc. (NASDAQ:SIOX) last year which is positive news for ... - Yahoo Sports
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 74 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 25.2 (%) |
| Held by Institutions | 25.5 (%) |
| Shares Short | 71 (K) |
| Shares Short P.Month | 367 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.4 % |
| Return on Equity (ttm) | -47.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -1.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2019-05-07 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|